Reasons for reconsidering the methods for the rapid detection of inherited metabolic disease in acutely ill children Biochemical profiles for the detection of inherited metabolic diseases (IMD) were first described about 20 years ago.' They were introduced to screen mentally subnormal populations for IMD and were aimed mainly at detecting abnormalities of amino acid and carbohydrate metabolism which were known at the time. Nowadays, most clinical chemistry laboratories perform a similar group of simple tests and chromatograms as a metabolic screening profile, but profiling tests are now being applied in many clinical situations other than those for which they were designed. Account has not been taken of subsequent developments of different classes of metabolic defect, or of the fact that the tests may be fallible in some circumstances, particularly in the newborn infant.
Diagnosis of inherited metabolic diseases in severely ill children
couples considering prenatal diagnosis because they were at risk for galactosaemia had had at least one previous child who could be presumed to have died of this condition, although it was not suspected at the time. In addition, it has been common experience that most babies shown to have galactosaemia by routine screening have died before the result is available, and with no clinical suspicion of the disease,"
With regard to other disorders, a careful screening study carried out in Boston, Massachusetts.t detected one clinically significant aminoacidopathy per 5000 births. Few laboratories could claim to achieve anything approaching this rate of diagnosis. Cases of organic acid disorders are also probably frequently missed. When a more positive approach to screening is adopted, there is a dramatic increase in the diagnosis of defects of amino acid and organic acid metabolism,"
The most important reason for making a diagnosis of an IMD, and making it quickly, is that simple treatment can usually avert the more severe clinical consequences and death. Although, for most IMD which are treatable, the earlier the diagnosis is made the better is the prognosis, some children whose lives are dramatically saved in the newborn period are shown to be handicapped on long-term follow-up," It is difficult to be sure whether damage has been sustained because of delay in diagnosis, or whether it is an inevitable consequence of the disorder. The establishment of a rapid diagnostic facility is of the Although there have been no really systematic utmost importance, if only to assess these factors. studies of the problem of diagnosing IMD in Even if the child's life cannot be saved, it is acutely ill children, there is reason to believe that, in extremely important to make a diagnosis. Only in most hospitals, some of these cases are being missed. this way can the risks in subsequent pregnancies be
Often families under investigation have had a assessed and the parents be given precise counselling previous child who died with symptoms suggestive about the chances of a recurrence of the disorder. of the particular IMD for which the parents are They may decide not to have more children, or eventually found to be at risk. Take, for example, because it is possible to carry out prenatal diagnosis galactosaemia. In one series," four out of five for a large number of IMD7 they may be able to 389 choose this option in future pregnancies. Prevention of the birth of more affected babies may not be necessary if the disorder is known to respond to early treatment which can be ensured once the risk has been detected. It must be emphasised that early suspicion of an IMD is vital because the appropriate fluid or tissue specimens are usually required from a live infant if a definitive diagnosis is to be made. It is rarely possible to perform satisfactory biochemical tests on samples taken during a postmortem examination. It is also unlikely that an IMD would first be considered post mortem, because few produce specific macroscopic tissue changes which are readily recognisable.
Reasons that the diagnosis of an inherited metabolic disease may be missed The possibility of a sick child having an IMD must be considered first by a paediatrician and then must be explored by the laboratory. Therefore, if a diagnosis is missed the responsibility may lie with the paediatrician, with the laboratory, or, because of a lack of communication, with both of them.
There are two main reasons why paediatricians may fail to suspect an IMD in a sick child. The first is that each disease is uncommon. Normally, a paediatrician would have little experience in diagnosing an IMD unless he had worked for some time in one of the few hospitals which has many cases referred to it. Secondly, IMD rarely has a characteristic presentation, particularly in the newborn. Rather, the child may present with symptoms similar to those of other more frequently occurring disorders which also cause acute illness, such as sepsis and cardiorespiratory diseases. Although it is understandable that the more common causes are considered first, it is unfortunate that other important conditions are often completely forgotten. The problem is sometimes compounded because sepsis can occur as a complication of an IMD.
Although some paediatricians may not recognise that an acutely ill child might have an IMD and so may fail to send the appropriate specimens for laboratory investigation, it is also true that some hospital laboratories are inundated with urine samples from babies whose condition or symptoms do not suggest that they are at risk for an IMD. In these circumstances, much laboratory time is wasted. Approximately half the cases of amino acid disorders are believed to be benign. These are often discovered when urine samples from neonates are screened, and it may be very difficult to ignore these biochemical findings.
The laboratory also must accept its share of the responsibility for missing diagnoses of IMD. As Holton indicated in the introduction, most laboratories are screening for only a small proportion of the disorders which are significant in the acutely ill child, and it is often not made clear to the paediatrician how inadequate the metabolic screen is. Unfortunately, this may lead the paediatrician to believe that a much wider spectrum of diseases is being excluded in the tests than is actually the case and to rule out the possibility of an existing inherited disorder.
Finally, it is important to emphasise the skill that is required both in carrying out and in interpreting the results of metabolic screening tests, especially using chromatographic procedures. All too often it is assumed that, because these are qualitative tests, they can be delegated to the most junior staff. In fact, much experience is required before the necessary confidence and competence is achieved. Furthermore, it is not always appreciated that in some circumstances the tests can give false negative results. The person reporting on metabolic screening results must be aware of all these problems and should recommend repeating the tests, or carrying out more sophisticated tests, when the need is indicated by strong clinical suspicion. Unless attention is paid to all the factors mentioned, diagnoses will be missed became of poor laboratory performance.
Approaches to the diagnosis of inherited metabolic diseases Not everyone would agree with the concept of screening for IMD. Before proceeding further it would be pertinent to discuss various diagnostic approaches.
The first possible approach is a screening programme for all newborn infants, as currently used for phenylketonuria. Such a programme has been extended in a few laboratories to include a number of other conditions such as galactosaemia, maplesyrup-urine disease and homocystinuria. This approach has the attraction that very high detection rates can be achieved, but the cost may not be considered justifiable for disorders other than phenylketonuria because of their low incidence. Also, as pointed out previously, for conditions like galactosaemia or maple-syrup-urine disease which present in a life-threatening way soon after birth, the result of the screen is often not available soon enough.
The second approach is a selective one in which the paediatrician, after considering all possibilities, makes a tentative diagnosis of one or more specific disorders, and requests the appropriate laboratory investigations for those particular conditions. This approach has the possible advantage of the selective approach to any laboratory investigation: first, because it is necessary to think critically, a more obscure diagnosis is less likely to be overlooked; secondly, more economical use of laboratory services is made. The disadvantage is that all paediatricians are required to have an encyclopaedic knowledge of and wide experience in IMD. In fact, even those with this expertise find it impossible to make specific predictions in many cases.
The third approach is the 'profiling' approach, in which a group of laboratory tests is performed to screen for a wide range of IMD. The criticism of this type of metabolic screen is that when the paediatrician looks to the laboratory to answer the general question 'Does the infant have a metabolic disorder?', the laboratory may be excluding only a limited range of diseases and the possibility of others is ignored. This criticism can be overcome if laboratories provide a comprehensive range of tests which can detect almost all known biochemical conditions which present acutely in the newborn period. It is imperative that the laboratory states quite clearly which diseases have been excluded and which other possibilities should be explored. The greatest justification for a comprehensive screen is the lack of specificity of presenting symptoms in the newborn. Many of the symptoms are common to disorders with very different biochemical causes.
On balance the metabolic screen is the most practical approach for the paediatrician and the laboratory. It should be made very easy to establish whether a severely ill child has a metabolic disease, bearing in mind that the laboratory still has a responsibility to explain clearly which diseases it has tested for, and which others should be considered, and to make sure that the correct specimens have been used.
Development of a programme for the detection of inheritedmetabolic diseases in acutely ill children
From the foregoing discussion the following questions can be formulated, the answers to which form the basis of a programme which is aimed at improving the detection of IMD in sick children:
1 What IMDs present acutely, particularly in the newborn? 2 What presenting symptoms are suggestive of an IMD? 3 What tests should be available in hospitals with special care facilities, bearing in mind that strict quality control is essential?
WHAT IMDS PRESENT WITH ACUTE SYMPTOMS?
Appendix 1 is a guide to the IMDs which may present with acute symptoms, usually in the newborn period. It is obvious that such a list cannot be exhaustive: new disorders are being continually identified and characterised, and occasionally a disorder which usually has a subacute presentation may appear in a more severe form.
WHAT ARE THE PRESENTING SYMPTOMS WHICH SUGGEST AN IMD?
Appendix 2 lists characteristic clinical features associated with acutely presenting disorders, but it is most important to stress that the disorders do not always present with their most characteristic features.
As mentioned previously, babies with galactosaemia may present with generalised failure to thrive, incorporating rapidly deteriorating illness and a fulminating infection rather than the classical clinical picture as itemised in Appendix 1; a marked acidosis is not an invariable feature of the organic acidurias. It is also important to recognise that disorders which have a very characteristic clinical presentation in later life may present in a nonspecific way in the newborn. Lesch-Nyhan syndrome, for example, which is readily recognisable in older children because of developmental retardation, choreoathetosis, selfmutilation, and gouty arthropathy, may cause hypotonia, vomiting, and swallowing difficulties in the neonate.
WHAT TESTS SHOULD BE AVAILABLE?
A primary examination A careful clinical history of all severely ill children, with details of the dietary intake, is obviously vital to making a diagnosis and to the interpretation of laboratory data. Preliminary biochemical, haematological, microbiological, and radiological investigations may give a lead to the final diagnosis.
The biochemical tests should include, at least, sodium, potassium, chloride and acid/base studies, calcium, bilirubin, and glucose. A few of the conditions listed in Appendix 1 are not amenable to a screening approach, but they should be indicated by the clinical picture and routine laboratory findings. Such disorders include congenital adrenal hyperplasia, glycogen storage diseases (particularly type II), and Menkes disease. If a diagnosis of any of these conditions is considered likely the problem must be referred immediately to a laboratory which has specialised facilities for their investigation.
The majority of IMDs in Appendix 1 can be screened for by a comprehensive group of tests which are discussed below:
(1) Spot tests Spot tests and amino-acid chromatography have been the basis of metabolic screening for many years. However, they have many shortcomings, and their value is questionable, especially now that alternative and more specific methods are available. Some may be of moderate use but should not be relied on to exclude a diagnosis. It is suggested that only two spot tests should be retained:
(a) Urine reducing substances Spot tests for reducing substances are used to detect disorders of galactose and fructose metabolism. However, there are several cases on record which indicate that the relevant sugar may not always present in the urine, even in a severely ill child. Therefore, when galactosaemia is suspected on clinical grounds a specific screen must be used to determine galactose-I-phosphate uridyl transferase deficiency (see below). Testing every child for fructose intolerance is not justified because the disorder is rare and because its presentation obviously coincides with the introduction into the diet of foods containing fructose. The diagnosis is usually confirmed by a fructose tolerance test. 8 If tests for reducing substances are positive it is necessary to perform TLC to identify the sugars. If the screening test is negative chromatography is not required.
(b) Urine 2, 4-dinitrophenylhydrazine tests for ketoacids
The test is a simple and extremely sensitive method of detecting urinary keto-acids which occur in a number of clinically significant IMDs. A positive result should be followed up by chromatography for keto-acids and perhaps for amino or organic acids. A negative result, however, does not exclude the possibility ofthe patient having an IMD, particularly an organic aciduria.
(2) Screening profiles (a) Sugar chromatography The sugar should be identified in urines with positive spot tests for reducing substances. It must be borne in mind that neonates often excrete moderate amounts of glucose, galactose, and lactose, but a heavy, predominant spot of galactose or fructose strongly suggests galactosaemia or fructose intolerance respectively; the child should be treated appropriately while further investigations are in progress. As with the spot tests, failure to find the sugars does not always exclude a diagnosis of a carbohydrate disorder.
(b) Screening test for galactose-l-phosphate uridyl transferase deficiency
Since not all children with galactosaemia resulting from galactose-I-phosphate uridyl transferase deficiency have galactosuria, and Holton since the disorder may present with very nonspecific symptoms, there is a good case for screening all severely ill children with the cheap and simple enzyme methods described by Beutler." This requires a small spot of blood on a filter paper.
(c) Amino acid chromatography Urine amino-acid chromatography should detect all amino acid disorders listed in Appendix 1. Particular care is required in the case of non-ketotic hyperglycinaemia. In some children with this condition the increase in blood and urine glycine is relatively small, and a quantitation of glycine in CSF provides a more certain diagnosis. Amino acid chromatograms may also give evidence of the presence of some urea cycle disorders or hyperammonaemias and organic acidaemias. The interpretation of urine amino-acid chromatograms is extremely complex and requires much experience and skill. A great deal of time is saved if an immediate decision can be made on which spots are significant and which are anomalies introduced by diet or drugs.
(d) Blood ammonia The urea cycle disorders and hyperammonaemias are extremely important causes of acute illness and ones which are frequently overlooked at present. Estimation of blood ammonia is most important in detecting these conditions; it is also a useful indication of such disorders as the organic acid urias and Reye's syndrome.
(e) Purine[pyrimidine chromatography
Urine chromatography to detect purine/pyrimidines has a useful place in detecting Lesch-Nyhan syndrome and orotic aciduria. Orotic acid accumulates as a direct consequence of an inherited block in uridine metabolism, but it also occurs as a secondary consequence in one of the urea cycle disorders, ornithine transcarbamylase deficiency, and may sometimes be found during acute attacks in two others, citrullinaemia and arginino-succinic aciduria. Chromatography screening for orotic acid is a useful adjunct to diagnosing these important disorders.
(f) Organic acid chromatography Gas-liquid chromatography of organic acids in urine is necessary for screening the many complicated disorders arising from defects in the metabolism of the branched chain amino acids. Once again, because of their often non-specific mode of presentation, it would seem justified to consider these disorders in all acutely ill children. Lactic acidosis, a feature of a wide variety of disorders, and dicarboxylic acidurias, which arise from a number of defects in the degradation of long chain fatty acids and of the amino acids tryptophan, lysine, and hydroxylysine, may also be detected by this method of screening. Interpretation of organic acid chromatograms can be complicated by interference from drugs and other artefacts and so requires much skill and experience. Many would suggest that organic acid chromatography should not be done without a gas chromatograph/mass spectrometer system, or at least without access to a mass spectrometer, (g) Bloodpyruvate and lactate When there is evidence of lactic acidosis, or a disorder of pyruvate metabolism, it is necessary to estimate blood pyruvate and lactate by specific enzyme methods or a GLC technique. Such disorders cannot be excluded by urinary organic acid methods alone.
How should metabolic screening be organised ?
The foregoing discussion describes an active approach to the detection of IMD in severely ill children and the comprehensive range of screening tests which should be available wherever such patients are being cared for. A description of the precise technical methods, equipment, expertise, and organisation which are required to perform these tests is beyond the scope of this paper, but certain general points are important.
In a few European countries the problem is being approached at district hospital level, with approved methods and systems of quality control. It seems unlikely that the resources for this arrangement would be made available in the UK and, therefore, a more flexible organisation will have to be adopted.
Apart from possible access to a mass spectrometer, the equipment and technical skills required are available in most routine laboratories. However, every district hospital may not have the degree of experience which is necessary for interpreting the results, particularly for tests which arise only infrequently, and so decisions may be made more slowly. The aim of any laboratory which provides a screening service should be to give a provisional diagnosis so that positive therapy can be instituted within 24 hours. Several days' unnecessary delay in making a decision about a patient can be brought about when a laboratory, unable to interpret an abnormal observation, needs to refer the matter to a second laboratory.
It seems more likely that one laboratory can be found to provide a service for several districts or for the Region. In extreme situations there seems no reason why the repertoire of screening tests should not be divided between two laboratories, provided the system is organised and co-ordinated efficiently, one person being responsible for the final interpretation of the results. Rapid transport of specimens can usually be arranged over long distances in these emergencies, and this is preferable to the work being done poorly and inefficiently at the local hospital. The one test which may cause problems in this respect is blood ammonia, for this has to be done very soon after the sample has been collected. It is to be hoped that a simple method for ammonia estimation will soon be available so that this can be done in any laboratory.
The problem discussed is one of providing a screening service for IMD with the object of making a provisional diagnosis. The definitive diagnosis can usually be made with less urgency while treatment is progressing. This is usually the job of a laboratory specialising in a disease or group of diseases. It is important that such facilities are available and that information on where particular tests are performed is readily found. A co-ordinated effort is now being made by the Society for 
